Investor Class Action Lawsuits Shrunk Last Year, As Did Settlements: Report

The number of investment fraud or securities class action lawsuits filed last year remained near historic lows, and investors who brought the claims only collected about a third of the money in 2014 that they typically collect each year, according to a recent report. 

The economic and financial consulting group Cornerstone Research released a report (PDF) this month on security class action filings and settlements in 2014, and compared those investor cases to prior years.

The group found that the number of claims filed last year were similar to those brought in 2013, but notes that both years had significantly fewer securities fraud class action lawsuits than other years. One of the few exceptions was where it came to pharmaceutical companies, which saw significant increases of investor lawsuits.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

“Plaintiffs filed 170 new federal class action securities cases (filings) in 2014 — four more than in 2013,” the report states. “The number of 2014 filings was 10 percent below the historic average of 189 filings observed annually between 1997 and 2013.”

The researchers also found that those plaintiffs collected only a fraction of the money overall, as plaintiffs in previous years. According to the report, the Maximum Dollar Loss (MDL) of companies due to securities class action lawsuits in 2014 was $215 billion. That is 66% below the historic annual average of $630 billion and is the lowest amount collected since 1997.

According to the report, drug companies are bucking the trend when it comes to securities lawsuits, increasing for the second year in a row. In 2014 there were 15 securities class action lawsuits filed against pharmaceutical companies. That compares to 14 in 2013 and 10 in both 2011 and 2012.

The group noted that since the mid-2000s, securities class action lawsuits have had a harder time getting to trial or settlement as dismissals of such cases increased. However, the final tally for 2014 is still in question.

“Filings have been dismissed at a rate of 59 percent and 58 percent in cohort years 2010 and 2011, respectively,” the report determined. “Dismissal rates for these years may edge higher as pending cases are resolved.”

The study found that from 1996 to 2013, 49% of securities class action lawsuits have ended in settlements, 41% has been dismissed and 9% are ongoing. Overall, less than one out of 100 cases ended in a jury verdict one way or another. However, the rate of dismissals began rising considerably since 2008, when it passed 51% for the first time since at least 1996 and may be earlier. The number of cases settled dropped to 11% by 2012 and low single digits in 2013 and 2014, but much of that drop is because many of those lawsuits are ongoing.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.